Target system
Patent 6777176 Issued on August 17, 2004. Estimated Expiration Date: 
April 30, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 30, 2021. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesHuman PAK65 Protein kinase required for Ras signal transduction Parallel SELEX™ Methods for screening for inhibitors of the transcription-enhancing activity of the X protein of hepatitis B virus Method to regulate CD40 signaling High-throughput screening assays for modulators of STAT4 and STAT6 activity Patent #: 6207391 InventorsAssigneeApplicationNo. 09845225 filed on 04/30/2001US Classes:435/4, MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP435/194Transferring phosphorus containing group (e.g., kineases, etc.(2.7))ExaminersPrimary: Borin, MichaelAttorney, Agent or FirmInternational ClassesC12Q 300C12N 912 AbstractThe bacterial phosphotransferase system (PTS) as a drug target system catalyses the uptake and phosphorylation of carbohydrates. It is further involved in signal transduction, e.g. catabolite repression, chemotaxis, and allosteric regulation of metabolic enzymes and transporters. It is ubiquitous in bacteria but does not occur in eukaryotes. This uniqueness and the pleiotropic function make the PTS a target for the development of new antimicrobials. Assays are described that lead to the discovery of compounds which uncouple the PTS, by acting as protein histidine/cysteine phosphatases. Uncoupling of the PTS leads to inhibition of carbohydrate transport, repression of catabolite controlled genes (e.g. certain virulence genes) and depletion of phosphoenolpyruvate. Compounds from combinatorial libraries with high affinity for phosphoenolpyruvate-protein-phosphatase (Enzyme 1) serve as lead structures for the development of inhibitors and uncouplers of the PTS. Peptides and organic compounds with antimicrobial activities are discovered using these assays. These peptides and organic compounds can be used to inhibit the phosphotransferase system or treat infectious diseases. These peptides and organic compounds can be formulated into pharmaceutical compositions.Other References
|
| ||||||||||||||
